The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 152.50
Bid: 150.00
Ask: 155.00
Change: -5.00 (-3.17%)
Spread: 5.00 (3.333%)
Open: 157.50
High: 157.50
Low: 152.50
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Jan 2014 07:00

RNS Number : 5233Y
Revolymer PLC
27 January 2014
 



27th January, 2014

Revolymer plc

Directorate Change

 

Revolymer plc ("Revolymer" or the "Company"), the British polymer technology company, announces today that its CEO, Dr Roger Pettman, will leave the Company with effect from 31 January, 2014.

Dr. Pettman has been CEO of the business since its inception in 2005 and led the flotation on the AIM Market in July 2012. He has played a significant role driving the development of a broad portfolio of polymer-based IP which is now being applied to improve the performance of a variety of consumer products within the fast moving consumer goods industry and other industrial markets.

The Company has recently used its technology to enter the nicotine gum market in Canada, and is exploring expansion of this business area to the EU and USA.

Dr Pettman's particular expertise within Revolymer has been in the establishment of the business, having identified the business model of using novel polymers to improve the performance of existing consumer products. He is now looking forward to working on establishing other new ventures. The Board thanks Dr. Pettman for his dedicated service to the Company over many years, and wishes him well in his new endeavours. The shares owned by Dr Pettman are subject to an orderly marketing agreement, which expires on 31 December 2014.

The Board is taking steps to identify a new CEO with the commercial and operational experience to execute the Company's strategy of delivering commercialisation deals for its IP portfolio. Dr Bryan Dobson, Chairman of the Revolymer Remuneration Committee, is leading the search for the Company.

In the meantime, Revolymer CFO and Company Secretary Rob Cridland will become acting CEO, working closely with Dr David Pears, Chief Technology Officer, and Dr Jonathan Swanston, who heads the commercialisation of the Company's nicotine gum globally.

Ends

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Rob Cridland

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Ginny Pulbrook / Malcolm Robertson

 

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG and other industrial markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within these global high value markets. Current applications for the Group's technologies are in the household products, personal care and coatings & adhesives markets (together "Consumer Specialties") and the medicated chewing gum and confectionery chewing gum (together "Gum") markets.

www.revolymer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUNUORSSAAUAR
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.